Inspire Advisors LLC Acquires 1,532 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Inspire Advisors LLC boosted its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 7.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,394 shares of the biotechnology company’s stock after acquiring an additional 1,532 shares during the quarter. Inspire Advisors LLC’s holdings in ADMA Biologics were worth $384,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ADMA. Janney Montgomery Scott LLC acquired a new stake in ADMA Biologics in the 3rd quarter valued at $1,454,000. Amalgamated Bank lifted its position in ADMA Biologics by 803.0% in the 3rd quarter. Amalgamated Bank now owns 68,169 shares of the biotechnology company’s stock valued at $1,363,000 after acquiring an additional 60,620 shares in the last quarter. Principal Financial Group Inc. boosted its stake in ADMA Biologics by 785.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock valued at $23,872,000 after purchasing an additional 1,059,394 shares during the last quarter. Sigma Planning Corp acquired a new position in ADMA Biologics during the 3rd quarter valued at about $300,000. Finally, Los Angeles Capital Management LLC increased its holdings in ADMA Biologics by 83.9% during the 3rd quarter. Los Angeles Capital Management LLC now owns 148,490 shares of the biotechnology company’s stock worth $2,968,000 after purchasing an additional 67,740 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Stock Performance

Shares of ADMA Biologics stock opened at $18.50 on Thursday. The company has a market cap of $4.37 billion, a PE ratio of 66.07 and a beta of 0.60. ADMA Biologics, Inc. has a 52 week low of $5.88 and a 52 week high of $23.64. The business has a 50 day moving average price of $16.67 and a 200-day moving average price of $17.95. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.